Ansuvimab

Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells[1].

Product Specifications

CAS Number

[2375952-29-5]

Product Name Alternative

Ansuvimab-zyk; mAb114

UNSPSC

12352203

Target

Filovirus

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/ansuvimab.html

Purity

99.90

Solubility

10 mM in DMSO

Smiles

[Ansuvimab]

Molecular Weight

(143.94 kDa)

References & Citations

[1]Lee A, et, al. Ansuvimab: First Approval. Drugs. 2021 Apr;81 (5) :595-598.|[2]Corti D, et, al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016 Mar 18;351 (6279) :1339-42.